Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2011

View Archived Issues

Curacyte terminates phase III study of PHP

Results from RUBY-1 trial investigating darexaban in acute coronary syndrome reported

Phase I/II trial assesses everolimus in tuberous sclerosis complex

Preclinical data presented on dual orexin OX1/OX2 receptor antagonist developed at Merck & Co.

Gilead discloses results from evaluation of HCV NS3/NS4A inhibitor in healthy volunteers

Randomized phase II trial evaluates alfuzosin in women with voiding dysfunction

Bayer Schering Pharma discloses novel progesterone receptor antagonists

Bristol-Myers Squibb divulges new serine protease inhibitors

New acetyl-CoA carboxylase inhibitors claimed by Bayer Schering Pharma

Scientists at Ironwood Pharmaceuticals present novel agents for pain

Duloxetine blocks psychostimulant effects

New glucocorticoid receptor ligands synthesized

Shire reflects on first half of 2011

PTC Therapeutics and Genzyme restructure collaboration agreement for ataluren

SuperGen to become Astex Pharmaceuticals

Avantra Biosciences changes name to Courtagen Life Sciences

Royal DSM and Sinochem establish global joint venture

Gilead to amend clinical trials of GS-9190 in HCV infection

SkyePharma completes proof-of-concept study of SKP-1052

European Commission approves Afinitor for new indication

Trastuzumab enters phase II trial in Paget's disease

Marketing authorization filed for tesamorelin in Argentina

OXiGENE restructures clinical programs for Zybrestat and OXI-4503

Addex Pharmaceuticals regains rights to metabotropic glutamate mGlu4 receptor PAM program

Mesoblast clear to initiate phase II trial of Revascor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...